Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBT Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBT Margin for 11 consecutive years, with 400.72% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 57657.0% to 400.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 608.53%, a 23197.0% increase, with the full-year FY2025 number at 608.53%, up 23197.0% from a year prior.
  • EBT Margin was 400.72% for Q4 2025 at Intellia Therapeutics, up from 760.14% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 6647.52% in Q4 2023 to a low of 23881.33% in Q3 2021.
  • A 5-year average of 1648.41% and a median of 776.23% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -2375604bps in 2021, then skyrocketed 2310050bps in 2022.
  • Intellia Therapeutics' EBT Margin stood at 621.69% in 2021, then fell by -24bps to 771.63% in 2022, then soared by 961bps to 6647.52% in 2023, then crashed by -115bps to 977.29% in 2024, then soared by 59bps to 400.72% in 2025.
  • Per Business Quant, the three most recent readings for NTLA's EBT Margin are 400.72% (Q4 2025), 760.14% (Q3 2025), and 720.21% (Q2 2025).